Oncology Times
Friday, April 13, 2012
SGO Restructures to Incorporate a 501(c)(6)
Showing posts with label SGO. Show all posts
Showing posts with label SGO. Show all posts
Wednesday, April 18, 2012
Tuesday, April 03, 2012
Friday, February 03, 2012
2012 conference notice: SGO Annual Meeting on Women's Cancer Austin, Texas March 24-27 (early bird deadline Feb 6th)
Blogger's Note:
the SGO has had for many years a tradition of a reduced fee for ovarian cancer advocates not to mention their inclusion- Dr David Mutch was instrumental in the inclusion of ovarian cancer advocates in the SGO's annual conference, which continues to be noteworthy, as this is not necessarily the 'standard' at all medical/oncology conferences
Registration fee: Advocate Supporter $325.00
~~~~~~~~~~~~~~~~~~
2012 Annual Meeting on Women's Cancer®
March 24-27, 2012
The Austin Convention Center
Austin, Texas
For the most up to date information, please visit our dedicated, interactive Annual Meeting website at www.sgomeetingsonwomenscancer.com
This meeting focuses on offering programming and cutting-edge scientific research that demonstrates the latest data the subspecialty has to offer.
Register for the Annual Meeting
Book your Hotel Room
Schedule of Events (opens in pdf)
SGO
is offering open access for all education sessions at the 2012 Annual
Meeting for all registration categories. This allows attendees access
to: Scientific Plenary Sessions, Sunrise Seminars, Education Forums,
Exhibit Hall and Social Functions. The registration price also includes
access to select ‘on-demand’ sessions through the 2012 Annual Meeting
Webcast. Revisit some of your favorite sessions or view those you might
have missed due to scheduling conflicts.Sunday, January 15, 2012
Jan 15th: New Symptom Indices Offer No Gain in Ovarian Ca - in Oncology/Hematology, Ovarian Cancer from MedPage Today
Action Points
- Explain that two new ovarian cancer symptom indices offered little advantage over the current Goff Index.
- Point out that for all three indices, sensitivity was lower for data obtained from the general practitioner's notes and highest for those interviewed over the telephone, ant that the specificity was largely unchanged
"This sobering news follows hard on the heels of a large U.S. randomized trial finding no benefit, and indeed some harm, to women who were screened annually with a transvaginal ultrasound exam and a CA-125 blood test compared with a usual care control group," they wrote, referring to the NIH-sponsored Prostate, Lung, Colon, and Ovary (PLCO) screening program (JAMA 2011; 305:2295-2303).
They said one question the ovarian cancer community needs to answer is where it should focus its efforts: On the time between when a tumor is large enough to cause mild symptoms and when it is large enough to cause symptoms that prompt women to call a physician, or on a better understanding of disease etiology, leading to better prevention and therapy.
"These other research directions remain critical as the search continues for better ways to find ovarian cancer early," they said.
Primary source: Journal of the National Cancer Institute
Source reference: Lim AWW, et al. "Predictive value of symptoms for ovarian cancer: Comparison of symptoms reported by questionnaire, interview, and general practitioner notes" J Natl Cancer Inst 2012; 104: 1-11. Additional source: Journal of the National Cancer Institute Source reference: Hartge P, Speyer JL. "Finding Ovarian Cancer" J Natl Cancer Inst 2012; DOI: 10.1093/jnci/drj518. |
|
Related Article(s): |
Thursday, June 02, 2011
Medical News: Group Issues Gyn Cancer Follow-Up Guidance - MedPage Today
For ovarian (epithelial) cancer, the committee recommended:
- Physical exam and review of symptoms: Every three months for two years, followed by increasing intervals
- Pap test: Not indicated
- CA-125: Optional
- Radiographic imaging: Insufficient data to support routine use
- Suspected recurrence: CT and/or PET, plus CA-125
- Physical exam and review of symptoms: Every two to four months for two years, then every six months or annually depending on histology
- Serum tumor markers: Every two to four months for two years, then every six months for sex-cord stromal tumors but no longer indicated for germ-cell tumors
- Radiographic imaging: Generally, not indicated or data lacking to support routine use
- Suspected recurrence: CT and tumor markers
Moreover, a survey of primary care providers showed that respondents believed transition of oncology patients could be improved with individualized patient summaries, guidelines for surveillance, and expedited referral for suspected recurrence, the committee members noted.
"Thus, the provision of up-to-date information and the education of both patients and physicians are mandatory," they wrote.
"Action Points
Point out that this report indicates that there is very little evidence that either routine cytologic procedures or imaging are sufficiently useful to detect ovarian and endometrial cancer recurrence and alter response rates to salvage therapy.
Note that this report suggests that the most effective method to detect recurrences is a taking a thorough history, performing a detailed physical examination, and educating patients about relevant symptoms."
SGO sets new standards to monitor recurrence of gynecologic cancer more effectively
"The article is “Post treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology recommendations: by Ritu Salani, MD, MBA; Floor J. Backes, MD; Michael Fung Kee Fung, MB, BS; Christine H. Holschneider, MD; Lynn P. Parker, MD; Robert E. Bristow, MD, MBA; and Barbara A. Goff, MD (doi: 10.1016/j.ajog.2011.03.008). It will appear in the American Journal of Obstetrics & Gynecology, Volume 204, Issue 6 (June 2011) published by Elsevier."
Saturday, March 19, 2011
Monday, March 14, 2011
Thursday, March 10, 2011
Wednesday, March 09, 2011
ELC : Imedex e-learning center March 8th, 2011 video (30 min) interviews from SGO
Note: requires password/registration to view videos (free), risk factors, hereditary, KRAS mutation/variant (in many other cancers as well), MiRnA, ICON7 (Avastin).....
Featured Activity:
Best of the Day: 2011 Society of Gynecologic Oncologists Annual Meeting on Women’s Cancer
Dr Bradley Monk interviews 6 nationally recognized experts in GYN oncology about their interpretations of clinically relevant data presented at the annual meeting. Drs Deborah Armstrong, Barbara Goff, Tom Herzog, Warner Huh, Robert Coleman, and Robert Burger comprise the esteemed faculty.
2011 journal issues - current content listings Jan/March 2011 including supplement (SGO meeting)
Articles in Press | Volume 120 (2011) | |
| Volume 120, Issue 3 - selected pp. 317-492 (March 2011) Technologic Innovations and Novel Surgical Approaches for Patients with Gynecologic Malignancies | |
| Volume 120, Issue 2 pp. 165-316 (February 2011) | |
 | Volume 120, Issue 1 pp. 1-164 (January 2011) | |
| Volume 120, Supplement 1 pp. S1-S150 (March 2011) ABSTRACTS PRESENTED FOR THE 42ND ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS, ABSTRACTS PRESENTED FOR THE 42ND ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS | |
Journal Gynecologic Oncology, Volume 120, Supplement 1, Pages S1-S150 (March 2011) abstracts to be presented at 2011 annual SGO meeting
Note: this journal is by subscription ($$$) for full access, the actual abstracts via this indexed list are not available - titles of presentations only - abstracts either have been previously published or to come
Volume 120, Supplement 1, Pages S1-S150 (March 2011)
ABSTRACTS PRESENTED FOR THE 42ND ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS
Orlando, FL USA
March 2011
Tuesday, March 08, 2011
worth reading - Medical News: SGO: PARP Inhibitor Active in Ovarian Cancer - in Meeting Coverage, SGO from MedPage Today
......"Antitumor activity was observed in heavily pretreated BRCA1 and BRCA2 mutation carriers, and preliminary antitumor activity was seen in patients with sporadic cancers," said Robert Wenham, MD, of the H. Lee Moffitt Cancer Center in Tampa, Fla...........During the initial dose-escalation phase, the patient population was enriched with BRCA1/2 mutation carriers. In the dose-expansion phase of the trial, investigators enrolled patients with sporadic platinum-resistant high-grade serous ovarian cancer......cont'd
Monday, March 07, 2011
Medical News: SGO: Ovarian Ca Patients Shortchanged by Medicare - in Meeting Coverage, SGO from MedPage Today
Action Points
- Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
- Explain that an analysis of NCI and Medicare databases found that less than 40% of patients over age 65 with advanced ovarian cancer received care that measures up to national standards.
- Note that this study found demographic factors -- including race, marital status, geographic location, and socioeconomic status -- affected whether patients over 65 received optimal treatment.
Sunday, March 06, 2011
Wednesday, March 02, 2011
HVO Welcomes Society of Gynecologic Oncologists as Sponsor
HVO Welcomes Society of Gynecologic Oncologists
as Sponsor
[Washington, DC - February 26, 2011] - Health Volunteers Overseas is pleased to announce that the Society of Gynecologic Oncologists has joined as a sponsor. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide. The WHO reports that in 2005, cancer accounted for 7.6 million of all deaths with more than 70% of these cancer deaths occurring in the developing world. WHO projects 9 million people will be dying from cancer in 2015. These startling statistics show the great need for oncology training in the developing world.
Subscribe to:
Posts
(
Atom
)
